Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Robert T. Brodell MD, FAAD Editor-in-Chief

Jane M. Grant-Kels MD, FAAD Advisory Board

See All Experts

featured

Published in Dermatology

Journal Scan / Research · October 28, 2021

Prevalence and Risk Factors for Cognitive Impairment in Patients With Psoriasis

Journal of the European Academy of Dermatology and Venereology: JEADV

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Steven Feldman MD, PhD

Journal of the European Academy of Dermatology and Venereology: JEADV

Prevalence and risk factors for cognitive impairment in patients with psoriasis

J Eur Acad Dermatol Venereol 2021 Sep 28;[EPub Ahead of Print], Y Kuang, Y Luo, X Yi, Q Wang, C Wang, M Shen, Y Fu, G Shu, R Li, L Zhu, P Pang, Y Zhang, W Zhu, X Chen, BT Chen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Prevalence and Risk Factors for Cognitive Impairment in Patients With Psoriasis

Additional Info

Prevalence and risk factors for cognitive impairment in patients with psoriasis

Further Reading

Local Recurrence, Metastasis, and Mortality Rates Among Patients With Thin and In Situ Melanomas

Suicidal and Self-Injurious Behaviors Among Patients With Psoriasis or Psoriatic Arthritis Treated With Biologics

Efficacy and Safety of Combined Topical 17α-Ethinyl Estradiol With Minoxidil vs Topical Minoxidil Alone in Patients With Female Pattern Hair Loss

Efficacy of Treatment With Secukinumab in Patients With Hidradenitis Suppurativa

Clinical Features and Treatment Outcomes Among Patients With Primary Cutaneous B-Cell Lymphomas

Clinical Characteristics and Outcomes of DPP-4 Inhibitor–Associated Bullous Pemphigoid

Efficacy and Safety of Tofacitinib vs Azathioprine in Patients With Alopecia Areata and Its Variants

Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Initially Treated With Baricitinib 4 mg

Association Between 5α-Reductase Inhibitor Use for Dermatologic Conditions and the Risk of Breast or Gynecologic Cancers

Safety and Effectiveness of a Targeted Alkali Thermolysis Patch for the Treatment of Patients With Primary Axillary Hyperhidrosis or Excessive Axillary Sweating

Outcomes of Continued Ritlecitinib Treatment Through Week 48 in Patients With Alopecia Areata With or Without Early Target Responses

Recently Updated